Eli Lilly is mentioned as a patent holder for GLP-1 products, facing competition from Hims & Hers.
Source Post
Hims & Hers Stock Is a MEGA Rally Coming? Multi‑Bagger Potential
The German Value InvestorMar 15, 2026
The German Value Investor is analyzing Hims & Hers (HIMS) as a potential turnaround stock, noting its significant price drop and the company's expansion into weight management and GLP-1 injections. Despite strong revenue growth and a recent move to profitability, concerns remain regarding high marketing spend, stock-based compensation diluting shareholder value, and intense competition in the GLP-1 market. The investor is not currently invested due to perceived high risks.
Linked Mentions
Tickers discussed in this post
Hims & Hers (HIMS) presents a potential turnaround opportunity with strong revenue growth and profitability, but faces risks from competition and high marketing costs, leading to a hold sentiment.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.